Deutsch English Français

Contact

EP1732561

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1732561

EP1732561 - COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 23.10.2009 Database last updated on 18.11.2024
Most recent event Tooltip	23.10.2009	Application deemed to be withdrawn	published on 25.11.2009 [2009/48]
Applicant(s)	For all designated states GLAXO GROUP LIMITED Glaxo Wellcome House, Berkeley Avenue Greenford, Middlesex UB6 0NN / GB
	[N/P]
Former [2006/51]	For all designated states GLAXO GROUP LIMITED Glaxo Wellcome House, Berkeley Avenue Greenford, Middlesex UB6 ONN / GB
Inventor(s)	01 / BROWN, Andrew, J., GlaxoSmithKline New Frontiers Science Park South, Third Avenue Harlow, Essex CM19 5AW / GB
	02 / CONNOR, Helen, Elizabeth, GlaxoSmithKline Gunnels Wood Road Stevenage, Hertfordshire SG1 2NY / GB
	03 / EATHERTON, Andrew, J., GlaxoSmithKline New Frontiers Science Park South, Third Avenue Harlow, Essex CM19 5AW / GB
	04 / GIBLIN, Gerard, M. P., GlaxoSmithKline New Frontiers Science Park South, Third Avenue Harlow, Essex CM19 5AW / GB
	05 / GREEN, Richard, Howard deceased / GB
	06 / JANDU, Karamjit, S., GlaxoSmithKline New Frontiers Science Park South, Third Avenue Harlow, Essex CM19 5AW / GB
	07 / KNOWLES, Richard, G., GlaxoSmithKline Gunnels Wood Road Stevenage, Hertfordshire SG1 2NY / GB
	08 / MITCHELL, William, L., GlaxoSmithKline New Frontiers Science Park South, Third Avenue Harlow, Essex CM19 5AW / GB
	09 / NAYLOR, Alan, GlaxoSmithKline New Frontiers Science Park South, Third Avenue Harlow, Essex CM19 5AW / GB
	10 / O'SHAUGHNESSY, Celestine, T., GlaxoSmithKline New Frontiers Science Park South, Third Avenue Harlow, Essex CM19 5AW / GB
	11 / PALOMBI, Giovanni, NiKem Research S.r.L. Via Zanbeletti, 25, Baranzate di Bollate I-20021 Milan / IT
	12 / RAWLINGS, Derek, A., GlaxoSmithKline New Frontiers Science Park South, Third Avenue Harlow, Essex CM19 5AW / GB
	13 / SLINGSBY, Brian, P., GlaxoSmithKline New Frontiers Science Park South, Third Avenue Harlow, Essex CM19 5AW / GB
	14 / TRALAU-STEWART, Catherine, Jane, GlaxoSmithKline Gunnels Wood Road Stevenage, Hertfordshire SG1 2NY / GB
	15 / WHITTINGTON, Andrew, Richard, GlaxoSmithKline Gunnels Wood Road Stevenage, Hertfordshire SG1 2NY / GB
	16 / WILLIAMSON, Richard, Alexander, GlaxoSmithKline Gunnels Wood Road Stevenage, Hertfordshire SG1 2NY / GB
	[2006/51]
Representative(s)	Knight, Lucie Viktoria GSK Legal & Compliance - Global Patents 79 New Oxford Street London WC1A 1DG / GB
	[N/P]
Former [2006/51]	Knight, Lucie Viktoria GlaxoSmithKline, C.I.P., CN925.1.980, Great West Road Brentford, Middlesex TW8 9GS / GB
Application number, filing date	05702088.5	01.02.2005
	[2006/51]
	WO2005GB00348
Priority number, date	GB20040002355	03.02.2004 Original published format: GB 0402355
	[2006/51]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2005074939
	Date:	18.08.2005
	Language:	EN
	[2005/33]
	Type:	A1 Application with search report
	No.:	EP1732561
	Date:	20.12.2006
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 18.08.2005 takes the place of the publication of the European patent application.
	[2006/51]
Search report(s)	International search report - published on:	EP	18.08.2005
Classification	IPC:	A61K31/505, A61P11/00, A61P37/00, A61P29/00	[2006/51]
	CPC:	A61K31/505 (EP,US); A61P1/02 (EP); A61P1/04 (EP); A61P1/06 (EP); A61P1/08 (EP); A61P1/12 (EP); (+) A61P1/16 (EP); A61P11/00 (EP); A61P11/02 (EP); A61P11/06 (EP); A61P11/14 (EP); A61P13/10 (EP); A61P13/12 (EP); A61P15/00 (EP); A61P15/10 (EP); A61P17/00 (EP); A61P17/02 (EP); A61P17/04 (EP); A61P17/06 (EP); A61P19/00 (EP); A61P19/02 (EP); A61P19/10 (EP); A61P21/00 (EP); A61P21/04 (EP); A61P25/00 (EP); A61P25/02 (EP); A61P25/04 (EP); A61P25/06 (EP); A61P25/14 (EP); A61P25/16 (EP); A61P25/18 (EP); A61P25/20 (EP); A61P25/24 (EP); A61P25/28 (EP); A61P25/30 (EP); A61P25/32 (EP); A61P25/34 (EP); A61P25/36 (EP); A61P27/02 (EP); A61P27/04 (EP); A61P27/06 (EP); A61P27/16 (EP); A61P29/00 (EP); A61P3/02 (EP); A61P3/10 (EP); A61P31/00 (EP); A61P31/12 (EP); A61P31/22 (EP); A61P35/00 (EP); A61P37/00 (EP); A61P37/02 (EP); A61P41/00 (EP); A61P43/00 (EP); A61P5/14 (EP); A61P7/06 (EP); A61P7/10 (EP); A61P9/00 (EP); A61P9/10 (EP) (-)
	C-Set:	A61K31/505, A61K2300/00 (EP,US)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/51]
Extension states	AL	Not yet paid
	BA	Not yet paid
	HR	05.07.2006
	LV	05.07.2006
	MK	Not yet paid
	YU	Not yet paid
Title	German:	KOMBINATION AUS CB2-MODULATOREN UND PDE4-HEMMERN ZUR VERWENDUNG IN DER MEDIZIN	[2006/51]
	English:	COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE	[2006/51]
	French:	COMBINAISON DE MODULATEURS DU CB2 ET D'INHIBITEURS DE LA PDE4 UTILISEE EN MEDECINE	[2006/51]
Entry into regional phase	05.07.2006	National basic fee paid
	05.07.2006	Designation fee(s) paid
	05.07.2006	Examination fee paid
Examination procedure	05.07.2006	Examination requested [2006/51]
	17.12.2008	Despatch of a communication from the examining division (Time limit: M04)
	28.04.2009	Application deemed to be withdrawn, date of legal effect [2009/48]
	02.06.2009	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2009/48]
Fees paid	Renewal fee
	05.02.2007	Renewal fee patent year 03
	08.02.2008	Renewal fee patent year 04
	Penalty fee
	Additional fee for renewal fee
	28.02.2009	05 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[Y]FR2839718 (SANOFI SYNTHELABO [FR]) [Y] 1-7 * abstract * * page 13, line 10 - page 14, line 5 *;
		[Y]WO02060447 (UNIV CONNECTICUT [US], et al) [Y] 1-7 * page 8, line 7 - line 18 * * page 2, line 1 - line 8 *;
		[Y]US5925768 (BARTH FRANCIS [FR], et al) [Y] 1-7 * column 1, paragraph 2 * * column 26, line 11 - line 29 *;
		[Y]WO9709315 (SIGNAL PHARM INC [US], et al) [Y] 4,5 * claims 1,36-44 *;
		[Y]WO02062750 (SCHERING CORP [US]) [Y] 1-7 * page 39, line 13 *;
		[Y]WO2004000807 (SCHERING CORP [US], et al) [Y] 1-7 * page 29, line 27 *;
		[PY]WO2004018433 (GLAXO GROUP LTD [GB], et al) [PY] 1-7 * the whole document *;
		[PY]WO2004018434 (GLAXO GROUP LTD [GB], et al) [PY] 1-7 * the whole document *;
		[PY]WO2004029026 (GLAXO GROUP LTD [GB], et al) [PY] 1-7 * the whole document *;
		[PY]WO2004029027 (GLAXO GROUP LTD [GB], et al) [PY] 1-7 * the whole document *;
		[PX]WO2004085385 (SCHERING CORP [US], et al) [PX] 1-3,6,7 * page 28, line 19 - line 25 *
		[Y] - HUANG Z ET AL, "The next generation of PDE4 inhibitors.", CURRENT OPINION IN CHEMICAL BIOLOGY. AUG 2001, (200108), vol. 5, no. 4, ISSN 1367-5931, pages 432 - 438, XP002325704 [Y] 1-7 * figure 1 * * page 432, column 1, paragraph 1 * DOI: http://dx.doi.org/10.1016/S1367-5931(00)00224-6
		[Y] - SOUNESS J E ET AL, "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.", IMMUNOPHARMACOLOGY. MAY 2000, (200005), vol. 47, no. 2-3, ISSN 0162-3109, pages 127 - 162, XP002325705 [Y] 1-7 * the whole document * * figures 3,4 * DOI: http://dx.doi.org/10.1016/S0162-3109(00)00185-5

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p